AIM Vaccine Advances with Breakthrough Serum-Free Rabies Vaccine

AIM Vaccine Co., Ltd. Class H ( (HK:6660) ) has issued an announcement.

AIM Vaccine Co., Ltd. has completed Phase III clinical trials and obtained a production license for its iterative serum-free rabies vaccine, marking a significant technological advancement. This vaccine, which does not contain animal serum, is expected to be the first of its kind on the global market, enhancing safety and reducing adverse reactions. The company plans to submit an application for drug marketing registration, aiming to solidify its leading position in the rabies vaccine industry. With the rabies vaccine market in China projected to grow significantly, AIM Vaccine’s product is poised to become a preferred choice for vaccination institutions, leveraging its innovative approach and large-scale production capabilities.

More about AIM Vaccine Co., Ltd. Class H

AIM Vaccine Co., Ltd. is a leading company in the biopharmaceutical industry, focusing on the development and production of vaccines. The company is particularly prominent in the rabies vaccine market, where it is the world’s second-largest supplier. AIM Vaccine is committed to technological innovation and has developed an iterative serum-free rabies vaccine.

YTD Price Performance: -33.22%

Average Trading Volume: 6,109,329

Technical Sentiment Consensus Rating: Buy

For a thorough assessment of 6660 stock, go to TipRanks’ Stock Analysis page.